Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Oscar Health, Inc. (OSCR) SEC Filings & Earnings Calls

EquiReason read 17 Oscar Health, Inc. SEC filings in the last 12 months. Latest: SC 13D/A on 2026-09-18 — Thrive Capital and Joshua Kushner filed Amendment No. 4 to Schedule 13D, reporting internal share transfers and distributions with no change in beneficial ownership or activist int.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

OSCROscar Health, Inc.Follow OSCR — free
Healthcare Plans · Healthcare
—
Price chart with a free account
Market cap
9.6B
P/E TTM
18.5
Dividend yield
—
52-week
—
Next earnings
5 Nov, in 12 days

Every filing, read

last 12 months · SEC

What happened, the numbers inside, guidance and risks. The original is one click away.

18 Sep 2026SC 13D/AThrive Capital and Joshua Kushner filed Amendment No. 4 to Schedule 13D, reporting internal share transfers and distributions with no change in beneficial ownership or activist intent.open

Figures in the filing · each found in the filing text

Beneficial Ownership Percentage · 2026-09-1812.1%
Read the original on SEC EDGAR ↗
18 Sep 2026SC 13D/ASchedule 13D/A: Thrive Capital Partners II, L.P. 12.1%SEC ↗
16 Sep 20268-K · 7.01Oscar Health improves FY26 guidance: MLR improved 50bps to 81-82%, earnings from operations raised $100M to $600-800M; revenue and SG&A reaffirmed.open

Figures in the filing · each found in the filing text

Medical Loss Ratio · FY202681.5%
Earnings from Operations · FY2026$700M

Guidance

FY26 MLR improved to 81.0-82.0% from 81.5-82.5%; FY26 earnings from operations raised to $600-800M from $500-700M; FY26 revenue reaffirmed $18.7-19.0B; FY26 SG&A expense ratio reaffirmed 15.6-16.1%

Improved FY26 guidance with better MLR and higher earnings from operations.

Read the original on SEC EDGAR ↗
7 Aug 202610-QOscar Health reported strong Q2 2026 results with revenue up 71% YoY, MLR improving to 79.2%, and net income of $362M, driven by membership growth and disciplined pricing.earningsopen

Figures in the filing · each found in the filing text

Total Revenue · Q2-2026$4.88B+70% y/y
Net Income (Loss) attributable to Oscar Health, Inc. · Q2-2026$362M
Medical Loss Ratio (MLR) · Q2-202679.2%
SG&A Expense Ratio · Q2-202614.2%

Risks flagged

Regulatory risk from ACA program integrity changes

“As of July 1, 2026, there were approximately 250 thousand to 300 thousand members who we expect will be retroactively disenrolled in connection with CMS program integrity requirements or fraud, waste and abuse laws and regulations.” · word for word

Risk adjustment estimation uncertainty

“Our risk transfer estimates are subject to a high degree of estimation and variability, and are affected by the relative risk of our members, and in the case of the ACA, that of other insurers.” · word for word
Read the original on SEC EDGAR ↗
6 Aug 20268-K · 2.02Total revenue $4.88B (+70% y/y); Medical loss ratio 79.2; SG&A expense ratio 14.2; Guidance: Earnings from operations guidance raised to $500M-$700M from $250M-$450M; MLR guidance improved to 81.5%-82.5% from 82.4%-83.4%; SG&A ratio guidancearningsopen

Figures in the filing · each found in the filing text

Total revenue · Q2-2026$4.88B+70% y/y
Medical loss ratio · Q2-202679.2%
SG&A expense ratio · Q2-202614.2%
Earnings from operations · Q2-2026$389M
Net income attributable to Oscar Health, Inc. · Q2-2026$362M
Adjusted EBITDA · Q2-2026$415M
Effectuated Membership - Individual and Small Group · Individual and Small Group · Q2-20262,963,002+47% y/y
Diluted earnings per share · Q2-2026$1.10

Guidance

Earnings from operations guidance raised to $500M-$700M from $250M-$450M; MLR guidance improved to 81.5%-82.5% from 82.4%-83.4%; SG&A ratio guidance improved to 15.6%-16.1% from 15.8%-16.3%.

Raised full-year 2026 guidance significantly, reflecting strong operating performance and disciplined execution.

Risks flagged

No significant new risks identified; prior period reserve development may not recur.

“Favorable prior period reserve development of $164M contributed to MLR improvement; may not be sustainable.”
Read the original on SEC EDGAR ↗
8 Jun 20268-K · 7.01Oscar Health reaffirms full year 2026 guidance at Goldman Sachs conference; no changes to prior outlook.open

Guidance

Reaffirmed full year 2026 guidance; no changes.

Risks flagged

No new risks identified; reaffirmation suggests no material change.

“No new risk factors disclosed.”
Read the original on SEC EDGAR ↗
2 Jun 20268-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)open

Risks flagged

Key technology leader moves to advisory role; potential loss of technical leadership.

“transition from President of Technology and Chief Technology Officer to Co-Founder & Advisor”
Read the original on SEC EDGAR ↗
7 May 202610-QTotal Revenue $4.65B (+53% y/y); Medical Loss Ratio 70.5; SG&A Expense Ratio 15.2open

Figures in the filing · each found in the filing text

Total Revenue · Q1-2026$4.65B+53% y/y
Medical Loss Ratio · Q1-202670.5%
SG&A Expense Ratio · Q1-202615.2%
Net Income Attributable to Oscar Health, Inc. · Q1-2026$679M+147% y/y

Risks flagged

ACA Subsidy Expiration and Regulatory Tightening

“We expect that the expiration of the eAPTCs, and the implementation of the Program Integrity Rules and the OBBBA could continue to negatively impact the size of the Health Insurance Marketplaces and our membership in future years.” · word for word

Risk Adjustment Estimation Uncertainty

“Our risk transfer estimates are subject to a high degree of estimation and variability, and are affected by the relative risk of our members, and in the case of the ACA, that of other insurers.” · word for word
Read the original on SEC EDGAR ↗
6 May 20268-K · 2.02Total revenue $4.65B (+53% y/y); Medical loss ratio 70.5; SG&A expense ratio 15.2; Guidance: Reaffirmed full year 2026 outlook across all metricsearningsopen

Figures in the filing · each found in the filing text

Total revenue · Q1-2026$4.65B+53% y/y
Medical loss ratio · Q1-202670.5%
SG&A expense ratio · Q1-202615.2%
Earnings from operations · Q1-2026$704M+137% y/y
Net income attributable to Oscar Health, Inc. · Q1-2026$679M+147% y/y
Adjusted EBITDA · Q1-2026$727M+121% y/y
Total Members · Q1-20263,174,489+56% y/y

Guidance

Reaffirmed full year 2026 outlook across all metrics

Reaffirmed 2026 guidance; on track to significantly expand margins and achieve meaningful profitability.

Risks flagged

Favorable prior period reserve development of $68M in Q1 2026 vs $31M unfavorable in Q1 2025; reserve development can be volatile.

“The Company had $68 million of favorable development in the first quarter of 2026 compared to $31 million of unfavorable development in the first quarter of 2025.” · word for word
Read the original on SEC EDGAR ↗
22 Apr 2026DEF 14AProxy statement filed for 2026 annual meeting, disclosing executive compensation, governance changes, and 2025 performance.open

Figures in the filing · each found in the filing text

Revenue · FY2025$11.70B+28% y/y
Loss from operations · FY2025$-396M
SG&A expense ratio · FY202517.5%
Membership · 2026-02-013,400,000
Market share · 2026-02-0130.0%
Direct & Assumed Premiums · FY2025$14.08B
Direct SG&A Ratio · FY202514.6%
Operating Margin · FY2025-3.4%
Net Income (Loss) · FY2025$-443M

Risks flagged

Market morbidity headwind

“The industry-wide increase in market morbidity, driven by factors such as Medicaid lives entering the market and program integrity initiatives, was a significant headwind throughout the year” · word for word

Regulatory uncertainty in ACA marketplace

“current dynamics in the Patient Protection and Affordable Care Act ('ACA') marketplace, including the regulatory environment, present considerable challenges in setting reliable three-year financial targets” · word for word
Read the original on SEC EDGAR ↗
21 Apr 20268-K · 7.01Issued a Regulation FD disclosure (forward guidance or material update); filed financial statements and exhibits with this reportopen

Guidance

Full-year 2026 guidance reaffirmed, indicating stable demand and positive management tone.

Read the original on SEC EDGAR ↗
2 Mar 20268-K · 7.01Oscar Health reaffirms full year 2026 guidance provided on Feb 10, 2026, at Raymond James conference. No new numbers or changes.open

Guidance

Reaffirms FY2026 guidance; no new numbers.

Read the original on SEC EDGAR ↗
13 Feb 202610-KEffectuated Members 2,042,449 (+22% y/y); Accumulated Deficit $3.29B (+16% y/y); Florida Members 1,179,934 (+35% y/y)open

Figures in the filing · each found in the filing text

Effectuated Members · FY20252,042,449+22% y/y
Accumulated Deficit · FY2025$3.29B+16% y/y
Florida Members · Florida · FY20251,179,934+35% y/y
Texas Members · Texas · FY2025358,910+155% y/y

Risks flagged

APTC Fraud Investigation

“On February 9, 2026, we received a subpoena from the Congressional Committee on the Judiciary requesting certain documents in connection with their examination of potential APTC fraud in the Health Insurance Marketplace.” · word for word

Profitability Uncertainty

“we did not achieve profitability in 2025, and we may not be able to do so again in the future.” · word for word

Regulatory Dependency

“Because we rely on the Health Insurance Marketplaces, any significant changes to the ACA, or other changes in state or federal healthcare law and regulation, could materially and adversely impact our business, financial condition, and results of operations.” · word for word
Read the original on SEC EDGAR ↗
10 Feb 20268-K · 1.01, 2.02, 2.03Oscar Health entered a credit agreement for a revolving credit facility with JPMorgan and other lenders, increasing leverage. Also reported Q4 and FY2025 earnings results.open

Risks flagged

Credit agreement includes standard representations and warranties; no material adverse change clause.

“Section 3.06. No Material Adverse Change” · word for word
Read the original on SEC EDGAR ↗
29 Dec 20258-K · 5.02CEO base salary $1M; CEO target bonus percentage 150; CEO equity grant value $45Mopen

Figures in the filing · each found in the filing text

CEO base salary · 2025-12-22$1M
CEO target bonus percentage · 2026150.0%
CEO equity grant value · 2026$45M

Risks flagged

CEO retention risk mitigated by extended contract and enhanced compensation

“A&R Employment Agreement extends term to April 2029 with automatic renewal, increased base salary and bonus, and $45M equity grant.”
Read the original on SEC EDGAR ↗
6 Nov 202510-QOscar reported Q3 2025 results with 23% revenue growth and 28% membership growth, but MLR deteriorated to 88.5% due to higher risk adjustment transfers.earningsopen

Figures in the filing · each found in the filing text

Total Revenue · Q3-2025$2.99B+23% y/y
Net Income (Loss) Attributable to Oscar Health, Inc. · Q3-2025$-137M
Medical Loss Ratio (MLR) · Q3-202588.5%
SG&A Expense Ratio · Q3-202517.5%
Membership · 2025-09-302,116,904+28% y/y

Risks flagged

Risk adjustment estimation uncertainty

“Our risk transfer estimates are subject to a high degree of estimation and variability, and are affected by the relative risk of our members, and in the case of ACA, that of other insurers.” · word for word

Enhanced APTC expiration risk

“If Congress does not take action, the enhanced APTCs will expire at the end of 2025. If the enhanced APTCs are not renewed, insurance coverage could become unaffordable for certain individuals.” · word for word

Tariff impact on medical costs

“If such tariffs are imposed, the potential impact could include, among other things, higher costs for medical providers and facilities, higher pharmaceutical prices, higher costs of medical devices, and supplies and shortages of certain medicines and medical supplies.” · word for word
Read the original on SEC EDGAR ↗
6 Nov 20258-K · 2.02, 8.01Total revenue $2.99B (+23% y/y); Medical loss ratio 88.5; SG&A expense ratio 17.5; Guidance: FY2025 revenue $12.0-12.2B, MLR 86-87%, SG&A 17.1-17.6%, operating loss $(300)-(200)Mearningsopen

Figures in the filing · each found in the filing text

Total revenue · Q3-2025$2.99B+23% y/y
Medical loss ratio · Q3-202588.5%
SG&A expense ratio · Q3-202517.5%
Net loss attributable to Oscar Health, Inc. · Q3-2025$-137M
Adjusted EBITDA · Q3-2025$-101M
Total Members · Q3-20252,116,904+28% y/y
Individual and Small Group members · Individual and Small Group · Q3-20252,111,736+32% y/y
Cigna+Oscar members · Cigna+Oscar · Q3-20255,168-90% y/y
Loss from operations · Q3-2025$-129M
Diluted earnings per share · Q3-2025$-0.53

Guidance

FY2025 revenue $12.0-12.2B, MLR 86-87%, SG&A 17.1-17.6%, operating loss $(300)-(200)M

Guidance reaffirmed; CEO confident in 2026 profitability; membership growth strong but MLR pressure from risk adjustment.

Risks flagged

Medical loss ratio increase due to higher risk adjustment transfers may persist.

“MLR 88.5% vs 84.6% YoY; $130M net risk adjustment accrual.”

Cigna+Oscar partnership decline indicates channel risk.

“Cigna+Oscar members dropped from 51,291 to 5,168 YoY.”

Net loss widening despite revenue growth; path to profitability uncertain.

“Net loss $(137.5)M vs $(54.6)M YoY.”
Read the original on SEC EDGAR ↗

Oscar Health, Inc. — questions

What did Oscar Health, Inc. file recently?
17 SEC filings in the last 12 months. Latest: SC 13D/A on 2026-09-18 — Thrive Capital and Joshua Kushner filed Amendment No. 4 to Schedule 13D, reporting internal share transfers and distributions with no change in beneficial ownership or activist intent.

Every figure on this page comes from Oscar Health, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.